Harpoon Therapeutics to Participate in Three Upcoming Virtual Investor Conferences
Harpoon Therapeutics (NASDAQ: HARP) announced that its CEO, Gerald McMahon, will participate in three virtual investor conferences in September 2021. The events include a panel discussion at Citi’s 16th Annual BioPharma Conference on September 9, a fireside chat at Baird’s 2021 Global Healthcare Conference on September 15, and another fireside chat at Cantor’s 2021 Virtual Global Healthcare Conference on September 28. Live webcasts will be accessible on the company’s website.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Gerald McMahon, Ph.D., President and Chief Executive Officer, will participate in three upcoming virtual investor conferences:
- A panel discussion (“Large Molecule Drugs for Oncology - Framing the Tip of the Spear for Novel Antibodies and Protein Therapeutics”) at Citi’s 16th Annual BioPharma Conference on Thursday, September 9, 2021 at 1:25 p.m. ET / 10:25 a.m. PT;
- A fireside chat at Baird’s 2021 Global Healthcare Conference on Wednesday, September 15, 2021 at 3:10 p.m. ET / 12:10 p.m. PT; and
- A fireside chat at Cantor’s 2021 Virtual Global Healthcare Conference on Tuesday, September 28, 2021 at 2 p.m. ET / 11 a.m. PT.
Live webcasts from the Citi and Cantor conference events will be available from the Events and Presentations section of the company’s website at https://ir.harpoontx.com/events-and-presentations and will be archived there shortly after the events.
About Harpoon Therapeutics
Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC®) platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. HPN424 targets PSMA and is in a Phase 1/2a trial for metastatic castration-resistant prostate cancer. HPN536 targets mesothelin and is in a Phase 1/2a trial for cancers expressing mesothelin, initially focused on ovarian and pancreatic cancers. HPN217 targets BCMA and is in a Phase 1/2 trial for relapsed, refractory multiple myeloma. HPN328 targets DLL3 and is in a Phase 1/2 trial for small cell lung cancer and other DLL3-associated tumors. Harpoon has also developed a proprietary ProTriTAC™ platform, which applies a prodrug concept to its TriTAC platform to create a therapeutic T cell engager that remains inactive until it reaches the tumor. For additional information about Harpoon Therapeutics, please visit www.harpoontx.com.
Contacts:
Harpoon Therapeutics, Inc.
Georgia Erbez
Chief Financial Officer
650-443-7400
media@harpoontx.com
Westwicke ICR
Robert H. Uhl
Managing Director
858-356-5932
robert.uhl@westwicke.com
FAQ
What events will Harpoon Therapeutics' CEO participate in September 2021?
When is Harpoon Therapeutics' participation in Citi’s BioPharma Conference?
Where can I watch the live webcasts for Harpoon Therapeutics' conferences?
What is Harpoon Therapeutics focused on developing?
What trials is Harpoon Therapeutics currently conducting?
